Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

被引：0
|
作者：
Pauline Corbaux
Audrey Lardy-Cleaud
Marie Alexandre
Maxime Fontanilles
Christelle Lévy
Alessandro Adriano Viansone
Audrey Mailliez
Marc Debled
Anthony Goncalves
Fanny Le Du
Florence Lerebours
Jean-Marc Ferrero
Jean-Christophe Eymard
Marie-Ange Mouret-Reynier
Thierry Petit
Jean-Sébastien Frenel
Florence Dalenc
Coralie Courtinard
Marie Chaix
Thomas Bachelot
机构：
[1] Centre Léon Bérard,Department of Medical Oncology
[2] Centre Léon Bérard,Biostatistics Unit, DRCI
[3] Institut Régional du Cancer de Montpellier,Department of Medical Oncology
[4] Centre Henri Becquerel,Department of Medical Oncology
[5] Centre François Baclesse,Department of Medical Oncology
[6] Institut Gustave Roussy,Department of Cancer Medicine
[7] Centre Oscar Lambret,Department of Medical Oncology
[8] Institut Bergonié,Department of Medical Oncology
[9] Institut Paoli-Calmettes,Department of Medical Oncology
[10] Centre Eugène Marquis,Department of Medical Oncology
[11] Institut Curie,Department of Medical Oncology
[12] Centre Antoine Lacassagne,Department of Medical Oncology
[13] Institut Jean Godinot,Department of Medical Oncology
[14] Centre Jean Perrin,Department of Medical Oncology
[15] Centre Paul Strauss,Department of Medical Oncology
[16] Institut de Cancérologie de l’Ouest René Gauducheau,Department of Medical Oncology
[17] Institut Claudius Regaud—IUCT Oncopole,Department of Medical Oncology
[18] Unicancer,Data Office
[19] Université de Bordeaux,Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219
[20] Centre Hospitalier Universitaire Dijon Bourgogne,Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2022年 / 191卷
关键词：
Advanced breast cancer; HR+/HER2−; Endocrine therapy; Chemotherapy; Progression-free survival; Real-word data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 207
页数：16
相关论文
共 50 条
  • [1] Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
    Corbaux, Pauline
    Lardy-Cleaud, Audrey
    Alexandre, Marie
    Fontanilles, Maxime
    Levy, Christelle
    Viansone, Alessandro Adriano
    Mailliez, Audrey
    Debled, Marc
    Goncalves, Anthony
    Le Du, Fanny
    Lerebours, Florence
    Ferrero, Jean-Marc
    Eymard, Jean-Christophe
    Mouret-Reynier, Marie-Ange
    Petit, Thierry
    Frenel, Jean-Sebastien
    Dalenc, Florence
    Courtinard, Coralie
    Chaix, Marie
    Bachelot, Thomas
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (01) : 191 - 207
  • [2] Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
    Reinert, Tomas
    Barrios, Carlos H.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (11) : 693 - 709
  • [3] Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
    Corbaux, P.
    Lardy-Cleaud, A.
    Alexandre, M.
    Fontanilles, M.
    Levy, C.
    Viansone, A. A.
    Mailliez, A.
    Debled, M.
    Goncalves, A.
    Le Du, F.
    Lerebours, F.
    Ferrero, J-M.
    Eymard, J-C.
    Mouret-Reynier, M-A.
    Petit, T.
    Frenel, J-S.
    Pons-Tostivint, E.
    Courtinard, C.
    Chaix, M.
    Bachelot, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S353 - S353
  • [4] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
  • [5] Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer
    Kinikoglu, Oguzcan
    Odabas, Hatice
    Altintas, Yunus Emre
    Yildiz, Anil
    Cakan, Burcin
    Akdag, Goncaguel
    Yildirim, Sedat
    Bal, Hamit
    Kaya, Tugba
    Tunbekici, Salih
    Isik, Deniz
    Basoglu, Tugba
    Yildirim, Mahmut Emre
    Turan, Nedim
    MEDICINA-LITHUANIA, 2024, 60 (06):
  • [6] Association of Endocrine Therapy with Survival for Patients with Small, Hormone Receptor-Positive, HER2-Negative, Breast Cancer
    Ma, S. J.
    Oladeru, O. T.
    Sood, A. J.
    Mikucki, M.
    Farrugia, M. K.
    Singh, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E74 - E74
  • [7] Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S7 - S8
  • [8] Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S7 - S8
  • [9] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [10] Untreated hormone receptor positive/HER2-negative metastatic breast cancer survival with front-line chemotherapy and maintenance endocrine therapy
    Sabatier, R.
    Meskine, A.
    Cappiello, M. A.
    Extra, J-M.
    Tarpin, C.
    Rousseau, F.
    Provansal, M.
    Bertucci, F.
    Viens, P.
    Goncalves, A.
    ANNALS OF ONCOLOGY, 2017, 28
12345